GlassScriptPhysician profile
Chitra Choudhary
NPI 1467749374
$4,792.88
in general payments reported to CMS, 2019-2025
19 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $244 · 2021: $1,118 · 2022: $221 · 2023: $2,701 · 2024: $67.13 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,911 · Food and Beverage: $567 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $435 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,910.63 |
| Food and Beverage | $566.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $435.00 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,872.34 | 2019-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $150.12 | 2023 | Recorlev |
| Amgen INC. | $118.67 | 2024-2025 | Tavneos, Tepezza |
| Novo Nordisk INC | $117.61 | 2019-2022 | |
| Lilly USA, LLC | $76.91 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $76.43 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.61 | 2019-2020 | |
| Abbott Laboratories | $39.38 | 2019 | |
| Insulet Corporation | $36.01 | 2020 | |
| Janssen Pharmaceuticals, INC | $33.57 | 2019-2020 | |
| Medtronic Minimed, INC. | $31.07 | 2019 | |
| Neurocrine Biosciences, INC. | $24.20 | 2025 | |
| Becton, Dickinson and Company | $24.02 | 2020 | |
| Recordati_rare_diseases_inc. | $23.68 | 2023 | Isturisa, Signifor Lar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $19.19 | 2025 | Unithroid |
| Chiesi USA, INC. | $15.74 | 2024 | Mycapssa |
| Beta Bionics, INC. | $15.12 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $15.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.